6533b82ffe1ef96bd1295e42
RESEARCH PRODUCT
ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy
Claudio CricelliRoberto FerrariMarino ScherilloGerardo MedeaAlberico Luigi CatapanoGiovanni Battista ZitoMauro CampaniniMaurizio AvernaSimona GiampaoliAndrea Di LenardaFrancesco RossiGiuseppe MusumeciPompilio FaggianoAttilio MaseriLeonardo BologneseEnzo BonoraGiorgio Cantelli FortiPasquale Perrone FilardiAldo P. MaggioniMarcello ArcaDamiano ParrettiGualtiero RicciardiCarmine RiccioRaffaele GriffoMaria Pia RuggieriFerruccio CeriottiEnrico PusineriMichele Massimo GuliziaFrancesco PerticoneFurio ColivicchiFrancesco RomeoAntonio Vittorio PannoNicoletta MusacchioFederico NardiMaurizio Giuseppe AbrignaniAlessandro MugelliMarcello CiaccioMaria Stella Grazianisubject
medicine.medical_specialtySettore MED/09 - Medicina InternaPCSK9 inhibitorMEDLINE030204 cardiovascular system & hematologyNOatherosclerosis; diagnostic and therapeutic pathways; hypercholesterolaemia; PCSK9 inhibitors; statins; sustainable health careDiagnostic and therapeutic pathways03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicine030212 general & internal medicineIntensive care medicineRisk managementCause of deathHypercholesterolaemiabusiness.industryAtherosclerotic cardiovascular diseaseCholesterolSustainable health careStatinsDiagnostic and therapeutic pathwayStatinHigh Cholesterol LevelsArticlesmedicine.diseaseAtherosclerosischemistryPCSK9 inhibitorsAtherosclerosiCardiologylipids (amino acids peptides and proteins)Atherosclerosis; Diagnostic and therapeutic pathways; Hypercholesterolaemia; PCSK9 inhibitors; Statins; Sustainable health care; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular Medicinebusinessmedicine.drugdescription
Atherosclerotic cardiovascular disease still represents the leading cause of death in western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proven effective in improving clinical outcomes. This document is focused on the clinical management of hypercholesterolemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health. The authors have considered with particular attention the role of hypercholesterolemia in the genesis of atherosclerotic cardiovascular disease. Besides, the implications of high cholesterol levels in the definition of the individual cardiovascular risk profile have been carefully analyzed, while all available therapeutic options for blood cholesterol reduction and cardiovascular risk mitigation have been considered. Finally, this document outlines the diagnostic and therapeutic pathways for the clinical management of patients with hypercholesterolemia.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-05-01 | European Heart Journal Supplements : Journal of the European Society of Cardiology |